Register Login

NOVAVAX INC (NVAX)

SymbolNVAX
NameNOVAVAX INC
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address21 FIRSTFIELD RD, GAITHERSBURG, MD None
Telephone240-268-2000
Fax—
Email—
Websitehttps://www.novavax.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001000694
Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Additional info from NASDAQ:
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

2026-09-02 21:03

Novavax to Participate in September Investor Conferences

Read more
2026-09-02 21:00

Novavax to Participate in September Investor Conferences

Read more
2026-08-28 12:32

Novavaxs Partnership Strategy Continues to Deliver with XFG-adaptedNuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

Read more
2026-08-28 12:30

Novavaxs Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

Read more
2026-08-07 11:26

New Form SCHEDULE 13G - NOVAVAX INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000510 <b>Size:</b> 8 KB

Read more
2026-08-06 12:03

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Read more
2026-08-06 12:00

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Read more
2026-07-30 11:02

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Read more
2026-07-30 11:00

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Read more
2026-06-23 23:58

Director Rodgers Richard J 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076930

Read more